<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39441542</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-3479</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>23</Day></PubDate></JournalIssue><Title>International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics</Title><ISOAbbreviation>Int J Gynaecol Obstet</ISOAbbreviation></Journal><ArticleTitle>Lipschütz ulcer following first dose of COVID-19 tozinameran vaccine: Report of a case and review of a World Health Organization pharmacovigilance database.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/ijgo.15941</ELocationID><Abstract><AbstractText>Lipschütz ulcer (LU) is a condition known for painful vulvar ulcers, typically affecting young women and often linked to infectious agents. Recent reports have indicated a potential connection between LU and COVID-19 vaccination, particularly after the second or booster doses. This study presents a case of LU following the first dose of tozinameran in a young woman who had a previous SARS-CoV-2 infection and investigates similar cases globally. An 18-year-old woman experienced vulvar pain and ulcers 2-days after her initial COVID-19 vaccine dose. After ruling out infections through serological tests, a diagnosis of LU was made, and her symptoms resolved after 10 days. A literature search and VigiBase® analysis revealed 11 cases of LU following COVID-19 vaccination, and 519 vulvovaginal ulcer cases associated with these vaccines were identified in Vigibase®, with a median onset of 2 days. Most LU cases occurred after the second dose or booster shots. The primary hypothesis for this association is a type 3 hypersensitivity reaction mediated by immune complexes, possibly triggered by prior exposure, as many cases occurred after the second dose. Interestingly, the presented case suggests that prior COVID-19 infection could serve as sensitization. In conclusion, this study highlights the potential occurrence of LU after the initial COVID-19 vaccine dose in young patients with prior COVID-19 infection. While the risk of recurrence after subsequent vaccinations or infections remains uncertain, the benefits of vaccination outweigh the risks. Clinicians and patients should be aware of this potential issue to make informed decisions regarding vaccination.</AbstractText><CopyrightInformation>© 2024 The Author(s). International Journal of Gynecology &amp; Obstetrics published by John Wiley &amp; Sons Ltd on behalf of International Federation of Gynecology and Obstetrics.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ewig</LastName><ForeName>Elliot</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Pharmacovigilance Center of Nice, University Hospital of Nice, Nice, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ben Othman</LastName><ForeName>Nouha</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-9346-5020</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology and Pharmacovigilance Center of Nice, University Hospital of Nice, Nice, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viard</LastName><ForeName>Delphine</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Pharmacovigilance Center of Nice, University Hospital of Nice, Nice, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gauci</LastName><ForeName>Pierre-Alexis</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Department of Gynecology, University Hospital of Nice, Nice, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rocher</LastName><ForeName>Fanny</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Pharmacovigilance Center of Nice, University Hospital of Nice, Nice, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drici</LastName><ForeName>Milou-Daniel</ForeName><Initials>MD</Initials><Identifier Source="ORCID">0000-0003-4121-530X</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology and Pharmacovigilance Center of Nice, University Hospital of Nice, Nice, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int J Gynaecol Obstet</MedlineTA><NlmUniqueID>0210174</NlmUniqueID><ISSNLinking>0020-7292</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID‐19 vaccine</Keyword><Keyword MajorTopicYN="N">Lipschütz ulcer</Keyword><Keyword MajorTopicYN="N">adverse drug reaction</Keyword><Keyword MajorTopicYN="N">sensitization</Keyword><Keyword MajorTopicYN="N">tozinameran</Keyword><Keyword MajorTopicYN="N">vulvar ulcers</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>12</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>12</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>11</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39441542</ArticleId><ArticleId IdType="doi">10.1002/ijgo.15941</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Haidari G, MacMahon E, Tong C, White J. Genital ulcers: it is not always simplex …. Int J STD AIDS. 2015;26(1):72‐73.</Citation></Reference><Reference><Citation>Govindan B. Lipschütz ulcers: a literature review based on 79 cases. EMJ Reprod Health. 2016;73‐78.</Citation></Reference><Reference><Citation>Mahé E, Longvert C, Saiag P. Ulcération ou érosion des muqueuses orales et/ou génitales. Rev Prat. 2006;56:667‐672.</Citation></Reference><Reference><Citation>MedDRA Hierarchy | MedDRA. 2023. https://www.meddra.org/how‐to‐use/basics/hierarchy</Citation></Reference><Reference><Citation>Faillie JL. Case‐non‐case studies: principle, methods, bias and interpretation. Therapie Avr. 2019;74(2):225‐232.</Citation></Reference><Reference><Citation>Lindquist M. VigiBase, the WHO global ICSR database system: basic facts. Drug Inf J DIJ Drug Inf Assoc. 2008;42(5):409‐419.</Citation></Reference><Reference><Citation>Hsu T, Sink JR, Alaniz VI, Zheng L, Mancini AJ. Acute genital ulceration after severe acute respiratory syndrome coronavirus 2 vaccination and infection. J Pediatr Juill. 2022;246:271‐273.</Citation></Reference><Reference><Citation>Wijaya M, Zhao C, Forward E, et al. Acute vulvar aphthous ulceration after COVID‐19 vaccination: 3 cases. J Low Genit Tract Dis Avr. 2022;26(2):186‐188.</Citation></Reference><Reference><Citation>Böttcher B, Schmidl‐Amann S, Toth B. Akute genitale Ulzerationen nach COVID‐19‐Infektion und Coronaimpfung. Gynäkol Endokrinol. 2023;21(1):78‐81.</Citation></Reference><Reference><Citation>Popatia S, Chiu YE. Vulvar aphthous ulcer after COVID‐19 vaccination. Pediatr Dermatol. 2022;39(1):153‐154.</Citation></Reference><Reference><Citation>Drucker A, Corrao K, Gandy M. Vulvar aphthous ulcer following Pfizer‐BioNTech COVID‐19 vaccine – a case report. J Pediatr Adolesc Gynecol. 2022;35(2):165‐166.</Citation></Reference><Reference><Citation>Wojcicki AV, O'Flynn O'Brien KL. Vulvar aphthous ulcer in an adolescent after Pfizer‐BioNTech (BNT162b2) COVID‐19 vaccination. J Pediatr Adolesc Gynecol Avr. 2022;35(2):167‐170.</Citation></Reference><Reference><Citation>Salusti‐Simpson M, Porter H, Fischer A. Acute vulvar ulcers and the COVID‐19 booster vaccine. JAAD Case Rep. 2022;26:82‐84.</Citation></Reference><Reference><Citation>Rudolph A, Savage DR. Vulval aphthous ulcers in adolescents following COVID‐19 vaccination‐analysis of an international case series. J Pediatr Adolesc Gynecol. 2023;36(4):383‐392.</Citation></Reference><Reference><Citation>Acute Vulvar Aphthous Ulceration After COVID‐19 Vaccination: 3 Cases. 2023. https://www.qgdigitalpublishing.com/article/Acute+Vulvar+Aphthous+Ulceration+After+COVID‐19+Vaccination%3A+3+Cases/4239498/741880/article.html</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>